Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (November 2024)
15 slides from Imagion Biosystems's investor presentation, Nov 27, 2024
Slide 1: MRI Imaging Agents for Cancer
MRI Imaging A Breakthrough in Molecular Magnetic Resonance Imaging Agents for Cancer Detection Imagion Biosystems Limited ASX:IBX 1 IBX Investor Webinar Copyright November 27 2024 | ImagionBiosystems.com
Slide 2: Imagion 2.0 Leadership
Imagion 2.0 Leadership Robert Proulx Ward Detwiler Melanie Leydin CA FGIA Brett Mitchell Executive Chairman Chief Business Officer Company Secretary & Non-Executive Non-Executive Director Director Robert is an operationally oriented Experienced early stage Melanie is a Chartered Accountant Mr. Mitch
Slide 3: Imagion Biosystems Overview
Imagion Biosystems Overview A clinical stage biotechnology company developing magnetic nanoparticle-based imaging and drug delivery technologies Molecular Imaging Lead Product Targeted nanoparticles have the potential to improve A Phase 1 study for the detection of nodal metastases in cancer detecti
Slide 4: An Unmet Need in Cancer Diagnosis
An Unmet Need in Cancer Diagnosis Screening Imaging Biopsy Conventional blood-based Current imaging To confirm if a lesion is malignant, biopsies tests, like PSA or CA125, methods can be used are taken which may be painful and cause indicate risk of cancer but to identify a “region patient complica-
Slide 5: Enabling Molecular Imaging
Enabling Molecular Imaging Conventional Imaging MagSense®Imaging Images provide anatomical context but are not Molecularly targeted imaging agents produce a specific and can only identify a region of distinct image pattern indicating the presence of a interest. tumor. 5 IBX Investor Webinar Copyrigh
Slide 6: How molecular MRI works
MagSense® nanoparticles enable molecular imaging by producing an identifiable change in image contrast when cancer cells are present How molecular MRI works • A targeting moiety (e.g. antibody or peptide) directs the nanoparticles to the target tissue to ensure Pre-Dose Post-Dose cancer specific det
Slide 7: MagSense Molecular Imaging
® MagSense Molecular Imaging MagSense® technology aims to transform how medical imaging can detect and diagnose cancer MRI-based Specific Safer Earlier Platform Detection Detection Technology Imaging agents work with Targeted imaging agents Does not require use of Would enable earlier detection Fits
Slide 8: Clinical Study – IBI010103
Clinical Study – IBI010103 Detection of Nodal Metastases in HER2+ Breast Cancer • A Phase 1 Study with 13 HER2+ Breast Cancer patients from 4 sites in Australia. • Imaging agent was safe and well tolerated in all 13 patients with no AE/SAEs reported related to the imaging agent. • Blinded review by
Slide 9: MagSense Use Cases
MagSense® Use Cases Detection of Nodal Metastases in Primary Tumor Detection Early Detection of Ovarian Cancer HER2+ Breast Cancer in Prostate Cancer Following primary tumor diagnosis determine if Following primary tumor diagnosis determine if Following elevated PSA blood test, the the cancer has sp
Slide 10: Rationale for MRI Imaging Agents
Rationale for MRI Imaging Agents Expanding access, Improving outcomes 1. There are >50,000 MRI scanners available globally (5x as many as PET imaging systems). 2. MagSense® imaging agents have long shelf life and can be stored and supplied by the hospital pharmacy without the costs and constraints l
Slide 11: Focus on Strategic Partnering
Sources: (1) JAMA Oncology. 2022. Medicare Payment Advisory Commission (MedPAC) and Centers for Medicare and Medicaid Services (CMS). Mordor Intelligence. Global Contrast Media Focus on Strategic Partnering Market 1. Use of contrast media is well established across medical imaging technologies with
Slide 12: Comparable Transactions
Comparable Transactions Acquirer Target Value AUD Year Notes Strategic investment. Part of $70M AUD $18M 2024 financing transaction. $35M revenue at time of transaction. $310M 2024 Breast cancer Imuno-oncology agent. Acquired $1.6B 2018 following successful Phase 3. All stock acquisition. Estimated
Slide 13: Path to Growth and Value
Path to Growth and Value Clinical Development Plan and Key Milestones $3-4B Market Completed 2024 - 2025 Opportunity HER2+ IND Nodal Testing and Breast Phase 1 Phase 2 Phase 3 Surveillance Cancer Dose and Image Protocol Optimization $200M+/yr IND Ovarian Primary Diagnosis and Cancer Pre-Clinical IND
Slide 14: Current Status and Priorities
Current Status and Priorities Shareholder General Meeting • December 9th at 10:30am AEDT – see Nov 7 th Notice of Meeting • Approve issuance of shares to complete $3M capital raise Clinical development of the MagSense ® imaging agent(s) to be resumed with new funding • Filing IND for MagSense® HER2
Slide 15: info@imagionbio.com | ASX:IBX
info@imagionbio.com | ASX:IBX 15 IBX Investor Webinar Copyright November 27 2024 | ImagionBiosystems.com
Imagion Biosystems — Investor Presentation (November 2024) on 6ix